Praecis begins phase 1 study of PPI-2458 cancer drug

By Angela McDaniels

Seattle, March 9 - Praecis Pharmaceuticals Inc. is conducting a phase 1 clinical study in cancer patients of PPI-2458, its orally administered investigational compound, according to a company news release.

The study will assess the safety, tolerability and pharmacodynamic activity of the compound.

PPI-2458 is a proprietary small molecule belonging to the fumagillin class of compounds that targets the methionine aminopeptidase-2 enzyme. The company said this class of compounds has been shown to prevent abnormal cell growth and the formation of new blood vessels, both of which contribute to the growth of aberrant tissues in diseases such as cancer and rheumatoid arthritis.

Praecis is a biopharmaceutical company based in Waltham, Mass., that develops therapies to address unmet medical needs or offer improvements over existing therapies.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.